Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The inspection concluded with zero Form 483 observations
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Subscribe To Our Newsletter & Stay Updated
